Research programme: antidepressants - UCB

Drug Profile

Research programme: antidepressants - UCB

Alternative Names: UCB-46331

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Class
  • Mechanism of Action Histamine H1 receptor antagonists; Serotonin 2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in Belgium (PO)
  • 11 Oct 2006 A lead compound from this programme has entered phase I development
  • 30 Mar 2006 Preclinical trials in Depression in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top